Gilead Sciences, Inc. (GILD)
| Market Cap | 151.59B |
| Revenue (ttm) | 29.09B |
| Net Income (ttm) | 8.11B |
| Shares Out | 1.24B |
| EPS (ttm) | 6.42 |
| PE Ratio | 19.00 |
| Forward PE | 14.30 |
| Dividend | $3.16 (2.59%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 8,294,114 |
| Open | 119.82 |
| Previous Close | 119.79 |
| Day's Range | 119.10 - 122.32 |
| 52-Week Range | 86.08 - 124.61 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 120.90 (-0.94%) |
| Earnings Date | Oct 30, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $120.9, which is a decrease of -0.94% from the latest price.
News
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of He...
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (...
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
Gilead Sciences, Inc. ( GILD) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury and Investor Relations Daniel O'Day - Chairman &...
Gilead posts higher profit as HIV sales rise, helped by prevention drugs
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Stree...
Gilead Sciences Announces Third Quarter 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfoli...
Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes
WASHINGTON--(BUSINESS WIRE)--Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes.
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
What To Expect From Gilead In Q3 2025
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On...
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The ...
Final Trade: F, HAL, MA, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlan...
Gilead's Trodelvy cuts breast cancer risk by 38% in trial
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically m...
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism, ...
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from Octob...
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic ...
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at t...
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
The Investment Committee give you their top stocks to watch for the second half.
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October ...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Dividend Shields: Top 5 Income Stocks
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cu...
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea , Sept.
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.